Literature DB >> 11107146

Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis?

B Hero1, T Simon, S Horz, F Berthold.   

Abstract

BACKGROUND: The purpose was to investigate the influence of metastatic pattern and primary extension over midline on prognosis of infants with metastatic neuroblastoma. PROCEDURE: Data of 317 consecutive infants with metastatic neuroblastoma were analyzed.
RESULTS: The amount of bone marrow infiltration (<10% vs. >10%) proved to be the most important factor and was more important than the presence of bone metastases. A disadvantage in outcome for patients with distant lymph node, intracranial, or atypical metastases or for patients with primary extension over midline could not be demonstrated. However, in the subgroup of patients treated with limited treatment, primary extension over midline proved a risk factor.
CONCLUSION: A redefinition of Stage 4S on an international basis is suggested. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11107146     DOI: 10.1002/1096-911x(20001201)35:6<683::aid-mpo43>3.0.co;2-f

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  10 in total

1.  Neuroblastoma with atypical metastases to cardiac and skeletal muscles: MRI features.

Authors:  Ricardo Faingold; Paul S Babyn; Shi-Joon Yoo; Anne I Dipchand; Sheila Weitzman
Journal:  Pediatr Radiol       Date:  2003-05-24

2.  Importance of recognizing differences between bone marrow and bone cortex.

Authors:  Mervyn Cohen; Aslam Siddiqui
Journal:  Pediatr Radiol       Date:  2005-12-07

3.  Hepatic metastatic disease in pediatric and adolescent solid tumors.

Authors:  Israel Fernandez-Pineda; John A Sandoval; Andrew M Davidoff
Journal:  World J Hepatol       Date:  2015-07-18

4.  A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

Authors:  Brian H Kushner; Kim Kramer; Shakeel Modak; Timothy J Akhurst; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2009-12-15       Impact factor: 3.167

5.  Experience with International Neuroblastoma Staging System and Pathology Classification.

Authors:  H Ikeda; T Iehara; Y Tsuchida; M Kaneko; J Hata; H Naito; M Iwafuchi; N Ohnuma; H Mugishima; Y Toyoda; M Hamazaki; J Mimaya; S Kondo; K Kawa; A Okada; E Hiyama; S Suita; H Takamatsu
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

6.  The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.

Authors:  Takahiro Tsutsumimoto; Paul Williams; Toshiyuki Yoneda
Journal:  J Bone Oncol       Date:  2014-10-31       Impact factor: 4.072

7.  Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Authors:  Cinzia Lavarino; Nai-Kong V Cheung; Idoia Garcia; Gema Domenech; Carmen de Torres; Miguel Alaminos; Jose Rios; William L Gerald; Brian Kushner; Mike LaQuaglia; Jaume Mora
Journal:  BMC Cancer       Date:  2009-02-03       Impact factor: 4.430

8.  Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP).

Authors:  G Schleiermacher; H Rubie; O Hartmann; C Bergeron; P Chastagner; F Mechinaud; J Michon
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

9.  PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma.

Authors:  Helen M Ameis; Astrid Drenckhan; Katharina von Loga; Gabriele Escherich; Katharina Wenke; Jakob R Izbicki; Konrad Reinshagen; Stephanie J Gros
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

10.  Effects of hypoxic preconditioning on neuroblastoma tumour oxygenation and metabolic signature in a chick embryo model.

Authors:  Yousef K Al-Mutawa; Anne Herrmann; Catriona Corbishley; Paul D Losty; Marie Phelan; Violaine Sée
Journal:  Biosci Rep       Date:  2018-08-29       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.